On February 9, 2026, GSK plc announced the vesting of Deferred Bonus Awards for its executives, with practical details including the exercise of nil-cost options and subsequent sales of shares to cover tax liabilities. Notably, these transactions involved 60,334 shares at £22.1140, 4,549 shares, and several other transactions for different executives reported on the same date.